Compare
Humacyte, Inc. vs Outlook Therapeutics, Inc. vs Dyadic International Inc vs Scinai Immunotherapeutics Ltd.
| Latest fiscal year | Humacyte, Inc. HUMA | Outlook Therapeutics, Inc. OTLK | Dyadic International Inc DYAI | Scinai Immunotherapeutics Ltd. SCNI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-09-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.04M | $1.41M | $3.09M | $1.31M |
| Revenue growth (YoY) | n/a | n/a | -11.6% | +99.2% |
| Gross margin | -376.1% (computed) | 4.0% | 24.9% (computed) | -202.3% |
| Operating margin | n/m | n/m | -232.8% | -575.3% |
| Net margin | n/m | n/m | -238.3% | -633.6% |
| Net income | -$40.83M | -$62.42M | -$7.36M | -$8.31M |
| EPS (Diluted) | -$0.26 | -$1.79 | -$0.23 | n/a |
| Operating cash flow | -$105.04M | -$51.83M | -$5.70M | -$6.03M |
| Free cash flow | -$105.93M | n/a | n/a | -$6.05M |
| Cash & equivalents | $50.50M | $8.08M | $4.62M | $1.66M |
| Total assets | $116.37M | $18.58M | $9.95M | $11.63M |
| Total liabilities | $113.26M | $50.77M | $8.71M | n/a |
| Shareholders' equity | $3.11M | -$32.19M | $1.23M | $8.10M |
| Return on year-end equity | n/m | n/a | -597.6% | -102.5% |
| Shares outstanding | 193.00M | 53.89M | 36.19M | 13.87B |
Revenue, most recent five fiscal years
| Fiscal year | Humacyte, Inc. | Outlook Therapeutics, Inc. | Dyadic International Inc | Scinai Immunotherapeutics Ltd. |
|---|---|---|---|---|
| Latest | $2.04M Ended 2025-12-31 | $1.41M Ended 2025-09-30 | $3.09M Ended 2025-12-31 | $1.31M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | n/a | $3.50M Ended 2024-12-31 | $658.0K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $2.90M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $2.93M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $2.40M Ended 2021-12-31 | n/a |